- Home
- IBG vs PRFX Comparison
IBG vs PRFX Comparison
Compare IBG & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBG | PRFX |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | Australia | Israel |
| Employees | 9 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5M | 1.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | IBG | PRFX |
|---|---|---|
| Price | $0.74 | $1.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 92.0K | 41.5K |
| Earning Date | 05-12-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.30 | $0.58 |
| 52 Week High | $6.50 | $3.71 |
Technical Indicators
Market Signals| Indicator | IBG | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 31.09 | 23.61 |
| Support Level | $0.69 | $1.27 |
| Resistance Level | $1.31 | $1.58 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 16.11 | 7.14 |
Price Performance
Historical ComparisonAbout IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.
About PRFX PainReform Ltd.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasise reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the Company's lead product, is based on the local anaesthetic ropivacaine and targets the postoperative pain relief market.